期刊
BEHAVIOURAL PHARMACOLOGY
卷 20, 期 8, 页码 755-758出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FBP.0b013e3283323c90
关键词
allodynia; hyperalgesia; Na-V 1.7; Na-V 1.8; rat; spared nerve injury
资金
- Gilead Sciences
- LSU Health Sciences Center Departments of Neurology and Pharmacology
- [5R29DA010356-04]
- [5K02DA 019656-03]
- [5R01 NS045954-04]
Ranolazine modulates the cardiac voltage-gated sodium channel (Na-V 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (Na-V 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain. Behavioural Pharmacology 20:755-758 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据